Adma Biologics (ADMA) Share-based Compensation (2011 - 2025)
Adma Biologics (ADMA) posted Share-based Compensation of $5.4 million for Q4 2025, up 6.84% on a QoQ basis from $5.0 million in Q3 2025, and down 0.75% year-over-year from $5.4 million in Q4 2024.
Adma Biologics (ADMA) Share-based Compensation (2011 - 2025) Analysis & Trends
Adma Biologics' Share-based Compensation history runs 13 years deep, the most recent figure standing at $5.4 million for Q4 2025.
- Quarterly Share-based Compensation fell 0.75% year-over-year to $5.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $20.0 million (up 47.08% YoY) and the FY2025 annual result came in at $20.0 million, up 47.08% from the prior year.
- Share-based Compensation was $5.4 million for Q4 2025 at Adma Biologics, up from $5.0 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $5.4 million in Q4 2024 and bottomed at $688274.0 in Q3 2021.
- A 5-year average of $2.4 million and a median of $1.7 million in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2023 — Share-based Compensation plunged 32.37% — and 2024, when it jumped 211.35%.
- Adma Biologics' Share-based Compensation stood at $1.2 million in 2021, then decreased by 11.88% to $1.1 million in 2022, then soared by 63.23% to $1.7 million in 2023, then soared by 211.35% to $5.4 million in 2024, then dropped by 0.75% to $5.4 million in 2025.
- Business Quant data shows ADMA's Share-based Compensation at $5.4 million in Q4 2025, $5.0 million in Q3 2025, and $5.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Adma Biologics | 1.99 Bn | 1.91 Bn | 88.82 Mn | 5.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.39 Mn |
| Dec 31, 2025 | 5.39 Mn |
| Sep 30, 2025 | 5.05 Mn |
| Sep 30, 2025 | 5.05 Mn |
| Jun 30, 2025 | 4.96 Mn |
| Jun 30, 2025 | 4.96 Mn |
| Mar 31, 2025 | 4.62 Mn |
| Mar 31, 2025 | 4.62 Mn |
| Dec 31, 2024 | 5.43 Mn |
| Dec 31, 2024 | 5.43 Mn |
| Sep 30, 2024 | 3.18 Mn |
| Sep 30, 2024 | 3.18 Mn |
| Jun 30, 2024 | 2.86 Mn |
| Jun 30, 2024 | 2.86 Mn |
| Mar 31, 2024 | 2.14 Mn |
| Mar 31, 2024 | 2.14 Mn |
| Dec 31, 2023 | 1.75 Mn |
| Dec 31, 2023 | 1.75 Mn |
| Sep 30, 2023 | 1.70 Mn |
| Sep 30, 2023 | 1.70 Mn |